全文获取类型
收费全文 | 42474篇 |
免费 | 1982篇 |
国内免费 | 120篇 |
专业分类
电工技术 | 480篇 |
综合类 | 235篇 |
化学工业 | 10387篇 |
金属工艺 | 778篇 |
机械仪表 | 917篇 |
建筑科学 | 1496篇 |
矿业工程 | 112篇 |
能源动力 | 1343篇 |
轻工业 | 6822篇 |
水利工程 | 362篇 |
石油天然气 | 225篇 |
武器工业 | 6篇 |
无线电 | 2849篇 |
一般工业技术 | 6061篇 |
冶金工业 | 6827篇 |
原子能技术 | 281篇 |
自动化技术 | 5395篇 |
出版年
2024年 | 89篇 |
2023年 | 330篇 |
2022年 | 1396篇 |
2021年 | 1827篇 |
2020年 | 962篇 |
2019年 | 1027篇 |
2018年 | 1177篇 |
2017年 | 1278篇 |
2016年 | 1294篇 |
2015年 | 1025篇 |
2014年 | 1484篇 |
2013年 | 2360篇 |
2012年 | 2118篇 |
2011年 | 2629篇 |
2010年 | 1934篇 |
2009年 | 1975篇 |
2008年 | 1789篇 |
2007年 | 1614篇 |
2006年 | 1270篇 |
2005年 | 1184篇 |
2004年 | 1237篇 |
2003年 | 1127篇 |
2002年 | 1066篇 |
2001年 | 860篇 |
2000年 | 665篇 |
1999年 | 678篇 |
1998年 | 2156篇 |
1997年 | 1450篇 |
1996年 | 1039篇 |
1995年 | 685篇 |
1994年 | 537篇 |
1993年 | 600篇 |
1992年 | 291篇 |
1991年 | 327篇 |
1990年 | 272篇 |
1989年 | 230篇 |
1988年 | 240篇 |
1987年 | 195篇 |
1986年 | 204篇 |
1985年 | 222篇 |
1984年 | 167篇 |
1983年 | 117篇 |
1982年 | 134篇 |
1981年 | 141篇 |
1980年 | 136篇 |
1979年 | 116篇 |
1978年 | 97篇 |
1977年 | 154篇 |
1976年 | 235篇 |
1975年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
201.
Ana Triguero-Martínez Emilia Roy-Vallejo Nuria Montes Hortensia de la Fuente Ana María Ortiz Santos Castaeda Isidoro Gonzlez-lvaro Amalia Lamana 《International journal of molecular sciences》2022,23(13)
Galectin 1 (Gal1) exerts immunomodulatory effects leading to therapeutic effects in autoimmune animal models. Patients with rheumatoid arthritis have been reported to show higher Gal1 serum levels than the healthy population. Our study aimed to find genetic variants on the Gal1 gene (LGALS1) modulating its expression and/or clinical features in patients with early arthritis (EA). LGALS1 was sequenced in 53 EA patients to characterize all genetic variants. Then, we genotyped rs9622682, rs929039, and rs4820293, which covered the main genetic variation in LGALS1, in 532 EA patients. Gal1 and IL-6 serum levels were measured by ELISA and Gal1 also by western blot (WB) in lymphocytes from patients with specific genotypes. Once disease activity improved with treatment, patients with at least one copy of the minor allele in rs9622682 and rs929039 or those with GG genotype in rs4820293 showed significantly higher Gal1 serum levels (p < 0.05). These genotypic combinations were also associated with higher Gal1 expression in lymphocytes by WB and lower IL-6 serum levels in EA patients. In summary, our study suggests that genetic variants studied in LGALS1 can explain heterogeneity in Gal1 serum levels showing that patients with higher Gal1 levels have lower serum IL-6 levels. 相似文献
202.
Adelina Orellana Pablo García-Gonzlez Sergi Valero Laura Montrreal Itziar de Rojas Isabel Hernndez Maitee Rosende-Roca Liliana Vargas Juan Pablo Tartari Ester Esteban-De Antonio Urszula Bojaryn Leire Narvaiza Emilio Alarcn-Martín Montserrat Alegret Daniel Alcolea Alberto Lle Lluís Trraga Vanesa Pytel Amanda Cano Marta Marqui Merc Boada Agustín Ruiz 《International journal of molecular sciences》2022,23(13)
Background: Clinical diagnosis of Alzheimer’s disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. However, the cutoffs currently published are usually reported by using cross-sectional datasets, not providing evidence about its intrinsic prognostic value when applied to real-world memory clinic cases. Methods: We quantified CSF Aβ1-42, Aβ1-40, t-Tau, and p181Tau with standard INNOTEST® ELISA and Lumipulse G® chemiluminescence enzyme immunoassay (CLEIA) performed on the automated Lumipulse G600II. Determination of cutoffs included patients clinically diagnosed with probable Alzheimer’s disease (AD, n = 37) and subjective cognitive decline subjects (SCD, n = 45), cognitively stable for 3 years and with no evidence of brain amyloidosis in 18F-Florbetaben-labeled positron emission tomography (FBB-PET). To compare both methods, a subset of samples for Aβ1-42 (n = 519), t-Tau (n = 399), p181Tau (n = 77), and Aβ1-40 (n = 44) was analyzed. Kappa agreement of single biomarkers and Aβ1-42/Aβ1-40 was evaluated in an independent group of mild cognitive impairment (MCI) and dementia patients (n = 68). Next, established cutoffs were applied to a large real-world cohort of MCI subjects with follow-up data available (n = 647). Results: Cutoff values of Aβ1-42 and t-Tau were higher for CLEIA than for ELISA and similar for p181Tau. Spearman coefficients ranged between 0.81 for Aβ1-40 and 0.96 for p181TAU. Passing–Bablok analysis showed a systematic and proportional difference for all biomarkers but only systematic for Aβ1-40. Bland–Altman analysis showed an average difference between methods in favor of CLEIA. Kappa agreement for single biomarkers was good but lower for the Aβ1-42/Aβ1-40 ratio. Using the calculated cutoffs, we were able to stratify MCI subjects into four AT(N) categories. Kaplan–Meier analyses of AT(N) categories demonstrated gradual and differential dementia conversion rates (p = 9.815−27). Multivariate Cox proportional hazard models corroborated these findings, demonstrating that the proposed AT(N) classifier has prognostic value. AT(N) categories are only modestly influenced by other known factors associated with disease progression. Conclusions: We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects. 相似文献
203.
Izadora de Souza Maria Carolina Clares Ramalho Camila Banca Guedes Isabeli Yumi Araújo Osawa Linda Karolynne Seregni Monteiro Luciana Rodrigues Gomes Clarissa Ribeiro Reily Rocha 《International journal of molecular sciences》2022,23(13)
Glioblastoma multiforme is a lethal disease and represents the most common and severe type of glioma. Drug resistance and the evasion of cell death are the main characteristics of its malignancy, leading to a high percentage of disease recurrence and the patients’ low survival rate. Exploiting the modulation of cell death mechanisms could be an important strategy to prevent tumor development and reverse the high mortality and morbidity rates in glioblastoma patients. Ferroptosis is a recently described type of cell death, which is characterized by iron accumulation, high levels of polyunsaturated fatty acid (PUFA)-containing phospholipids, and deficiency in lipid peroxidation repair. Several studies have demonstrated that ferroptosis has a potential role in cancer treatment and could be a promising approach for glioblastoma patients. Thus, here, we present an overview of the mechanisms of the iron-dependent cell death and summarize the current findings of ferroptosis modulation on glioblastoma including its non-canonical pathway. Moreover, we focused on new ferroptosis-inducing compounds for glioma treatment, and we highlight the key ferroptosis-related genes to glioma prognosis, which could be further explored. Thereby, understanding how to trigger ferroptosis in glioblastoma may provide promising pharmacological targets and indicate new therapeutic approaches to increase the survival of glioblastoma patients. 相似文献
204.
Giulia Gizzi Samuela Cataldi Claudia Mazzeschi Elisa Delvecchio Maria Rachele Ceccarini Michela Codini Elisabetta Albi 《International journal of molecular sciences》2022,23(13)
The relationship between cholesterol and cancer has been widely demonstrated. Clinical studies have shown changes in blood cholesterol levels in cancer patients. In parallel, basic research studies have shown that cholesterol is involved in the mechanisms of onset and progression of the disease. On the other hand, anorexic patients have high cholesterol levels and a high susceptibility to cancer. In this review, we first present a brief background on the relations among nutrition, eating disorders and cancer. Using several notable examples, we then illustrate the changes in cholesterol in cancer and in anorexia nervosa, providing evidence for their important relationship. Finally, we show a new possible link between cholesterol disorder in cancer and in anorexia nervosa. 相似文献
205.
Camila Reyes Estefanía Nova-Lamperti Daniel Duran-Sandoval Daniela Rojas Jorge Gajardo Enrique Guzman-Gutierrez Camila Bustos-Ruiz Valeska Ormazbal Felipe A. Zúiga Carlos Escudero Claudio Aguayo 《International journal of molecular sciences》2022,23(13)
Oxidized low-density lipoprotein (ox-LDL) is the most harmful form of cholesterol associated with vascular atherosclerosis and hepatic injury, mainly due to inflammatory cell infiltration and subsequent severe tissue injury. Lox-1 is the central ox-LDL receptor expressed in endothelial and immune cells, its activation regulating inflammatory cytokines and chemotactic factor secretion. Recently, a Lox-1 truncated protein isoform lacking the ox-LDL binding domain named LOXIN has been described. We have previously shown that LOXIN overexpression blocked Lox-1-mediated ox-LDL internalization in human endothelial progenitor cells in vitro. However, the functional role of LOXIN in targeting inflammation or tissue injury in vivo remains unknown. In this study, we investigate whether LOXIN modulated the expression of Lox-1 and reduced the inflammatory response in a high-fat-diet mice model. Results indicate that human LOXIN blocks Lox-1 mediated uptake of ox-LDL in H4-II-E-C3 cells. Furthermore, in vivo experiments showed that overexpression of LOXIN reduced both fatty streak lesions in the aorta and inflammation and fibrosis in the liver. These findings were associated with the down-regulation of Lox-1 in endothelial cells. Then, LOXIN prevents hepatic and aortic tissue damage in vivo associated with reduced Lox-1 expression in endothelial cells. We encourage future research to understand better the underlying molecular mechanisms and potential therapeutic use of LOXIN. 相似文献
206.
Ilaria Saltarella Concetta Altamura Aurelia Lamanuzzi Benedetta Apollonio Angelo Vacca Maria Antonia Frassanito Jean-Franois Desaphy 《International journal of molecular sciences》2022,23(13)
Ion channels are pore-forming proteins that allow ions to flow across plasma membranes and intracellular organelles in both excitable and non-excitable cells. They are involved in the regulation of several biological processes (i.e., proliferation, cell volume and shape, differentiation, migration, and apoptosis). Recently, the aberrant expression of ion channels has emerged as an important step of malignant transformation, tumor progression, and drug resistance, leading to the idea of “onco-channelopathy”. Here, we review the contribution of ion channels and transporters in multiple myeloma (MM), a hematological neoplasia characterized by the expansion of tumor plasma cells (MM cells) in the bone marrow (BM). Deregulation of ion channels sustains MM progression by modulating intracellular pathways that promote MM cells’ survival, proliferation, and drug resistance. Finally, we focus on the promising role of ion channels as therapeutic targets for the treatment of MM patients in a combination strategy with currently used anti-MM drugs to improve their cytotoxic activity and reduce adverse effects. 相似文献
207.
Francisco J. Osuna-Prieto Francisco M. Acosta Unai A. Perez de Arrilucea Le Floch Blanca Riquelme-Gallego Elisa Merchan-Ramirez Huiwen Xu Juan Carlos De La Cruz-Mrquez Francisco J. Amaro-Gahete Jose A. Llamas-Elvira Eva M. Trivio-Ibez Antonio Segura-Carretero Jonatan R Ruiz 《Journal of the International Society of Sports Nutrition》2022,19(1):417
208.
Eline A. M. Ruigrok Nicole S. Verkaik Erik de Blois Corrina de Ridder Debra Stuurman Stefan J. Roobol Dik C. Van Gent Marion de Jong Wytske M. Van Weerden Julie Nonnekens 《International journal of molecular sciences》2022,23(14)
Prostate specific membrane antigen targeted radionuclide therapy (PSMA-TRT) is a promising novel treatment for prostate cancer (PCa) patients. However, PSMA-TRT cannot be used for curative intent yet, thus additional research on how to improve the therapeutic efficacy is warranted. A potential way of achieving this, is combining TRT with poly ADP-ribosylation inhibitors (PARPi), which has shown promising results for TRT of neuroendocrine tumor cells. Currently, several clinical trials have been initiated for this combination for PCa, however so far, no evidence of synergism is available for PCa. Therefore, we evaluated the combination of PSMA-TRT with three classes of PARPi in preclinical PCa models. In vitro viability and survival assays were performed using PSMA-expressing PCa cell lines PC3-PIP and LNCaP to assess the effect of increasing concentrations of PARPi veliparib, olaparib or talazoparib in combination with PSMA-TRT compared to single PARPi treatment. Next, DNA damage analyses were performed by quantifying the number of DNA breaks by immunofluorescent stainings. Lastly, the potential of the combination treatments was studied in vivo in mice bearing PC3-PIP xenografts. Our results show that combining PSMA-TRT with PARPi did not synergistically affect the in vitro clonogenic survival or cell viability. DNA-damage analysis revealed only a significant increase in DNA breaks when combining PSMA-TRT with veliparib and not in the other combination treatments. Moreover, PSMA-TRT with PARPi treatment did not improve tumor control compared to PSMA-TRT monotherapy. Overall, the data presented do not support the assumption that combining PSMA-TRT with PARPi leads to a synergistic antitumor effect in PCa. These results underline that extensive preclinical research using various PCa models is imperative to validate the applicability of the combination strategy for PCa, as it is for other cancer types. 相似文献
209.
Henrique J. C. B. Gouveia Mercedes V. Urquiza-Martínez Raul Manhes-de-Castro Brbara J. R. Costa-de-Santana Jos Prez Villarreal Rosalío Mercado-Camargo Luz Torner Jailane de Souza Aquino Ana E. Toscano Omar Guzmn-Quevedo 《International journal of molecular sciences》2022,23(15)
Diets high in bioactive compounds, such as polyphenols, have been used to mitigate metabolic syndrome (MetS). Polyphenols are a large group of naturally occurring bioactive compounds, classified into two main classes: non-flavonoids and flavonoids. Flavonoids are distributed in foods, such as fruits, vegetables, tea, red wine, and cocoa. Studies have already demonstrated the benefits of flavonoids on the cardiovascular and nervous systems, as well as cancer cells. The present review summarizes the results of clinical studies that evaluated the effects of flavonoids on the components of the MetS and associated complications when offered as supplements over the long term. The results show that flavonoids can significantly modulate several metabolic parameters, such as lipid profile, blood pressure, and blood glucose. Only theaflavin and catechin were unable to affect metabolic parameters. Moreover, only body weight and body mass index were unaltered. Thus, the evidence presented in this systematic review offers bases in support of a flavonoid supplementation, held for at least 3 weeks, as a strategy to improve several metabolic parameters and, consequently, reduce the risk of diseases associated with MetS. This fact becomes stronger due to the rare side effects reported with flavonoids. 相似文献
210.
Elisa Boschetti Leonardo Caporali Roberto DAngelo Carolina Malagelada Anna Accarino Maria Teresa Dotti Roberta Costa Giovanna Cenacchi Loris Pironi Rita Rinaldi Vincenzo Stanghellini Stefano Ratti Lucia Manzoli Valerio Carelli Roberto De Giorgio 《International journal of molecular sciences》2022,23(15)
mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE) is a rare genetic disorder characterized by thymidine phosphorylase (TP) enzyme defect. The absence of TP activity induces the imbalance of mitochondrial nucleotide pool, leading to impaired mitochondrial DNA (mtDNA) replication and depletion. Since mtDNA is required to ensure oxidative phosphorylation, metabolically active tissues may not achieve sufficient energy production. The only effective life-saving approach in MNGIE has been the permanent replacement of TP via allogeneic hematopoietic stem cell or liver transplantation. However, the follow-up of transplanted patients showed that gut tissue changes do not revert and fatal complications, such as massive gastrointestinal bleeding, can occur. The purpose of this study was to clarify whether the reintroduction of TP after transplant can recover mtDNA copy number in a normal range. Using laser capture microdissection and droplet-digital-PCR, we assessed the mtDNA copy number in each layer of full-thickness ileal samples of a naive MNGIE cohort vs. controls and in a patient pre- and post-TP replacement. The treatment led to a significant recovery of gut tissue mtDNA amount, thus showing its efficacy. Our results indicate that a timely TP replacement is needed to maximize therapeutic success before irreversible degenerative tissue changes occur in MNGIE. 相似文献